WallStSmart

Lineage, Inc. Common Stock (LINE)vsReal Brokerage Inc (REAX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 140% more annual revenue ($5.37B vs $2.24B). REAX leads profitability with a -0.7% profit margin vs -3.1%. LINE earns a higher WallStSmart Score of 35/100 (F).

LINE

Avoid

35

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 5.0Quality: 3.0
Piotroski: 2/9Altman Z: 0.67

REAX

Avoid

33

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 6.3
Piotroski: 4/9Altman Z: 14.75

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

REAX2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
14.7510/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
29.6%8/10

Revenue surging 29.6% year-over-year

Areas to Watch

LINE4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.7%3/10

Operating margin of 3.7%

Debt/EquityHealth
1.013/10

Elevated debt levels

REAX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$392.95M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.7%3/10

Operating margin of 0.7%

Price/BookValuation
56.3x2/10

Trading at 56.3x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : REAX

The strongest argument for REAX centers on Altman Z-Score, Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum.

Bear Case : LINE

The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.

Bear Case : REAX

The primary concerns for REAX are EPS Growth, Market Cap, Operating Margin.

Key Dynamics to Monitor

LINE profiles as a turnaround stock while REAX is a growth play — different risk/reward profiles.

LINE carries more volatility with a beta of 0.88 — expect wider price swings.

REAX is growing revenue faster at 29.6% — sustainability is the question.

LINE generates stronger free cash flow (186M), providing more financial flexibility.

Bottom Line

LINE scores higher overall (35/100 vs 33/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.

Visit Website →

Real Brokerage Inc

REAL ESTATE · REAL ESTATE SERVICES · USA

Real Brokerage Inc. is a technology-driven residential real estate brokerage company. The company is headquartered in Toronto, Canada.

Visit Website →

Want to dig deeper into these stocks?